Management of bone disease in women after breast cancer

被引:14
|
作者
Milat, F. [1 ,2 ]
Vincent, A. J. [1 ,3 ]
机构
[1] Monash Hlth, Dept Endocrinol, Clayton, Vic, Australia
[2] Hudson Inst Med Res, Clayton, Vic, Australia
[3] Monash Univ, Sch Publ Hlth & Prevent Med, Monash Ctr Hlth Res & Implementat, Clayton, Vic 3168, Australia
关键词
BREAST CANCER; BONE HEALTH; OSTEOPOROSIS; MANAGEMENT; ADJUVANT ENDOCRINE THERAPY; ESTROGEN-RECEPTOR-ALPHA; PLUS ZOLEDRONIC ACID; POSTMENOPAUSAL WOMEN; PREMENOPAUSAL WOMEN; MINERAL DENSITY; AROMATASE INHIBITOR; OVARIAN SUPPRESSION; DOUBLE-BLIND; TIME-COURSE;
D O I
10.3109/13697137.2015.1100383
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Breast cancer and osteoporosis are common conditions affecting women, particularly following menopause. With increasing breast cancer incidence, effects of therapies and decreasing mortality, issues relating to the preservation of bone health with breast cancer therapy have become a priority. Contributing factors to bone loss and fractures in women with breast cancer include tumor effects, estrogen deprivation secondary to breast cancer therapies (chemotherapy, ovarian ablation or aromatase inhibitors), natural menopause and secondary causes of bone loss, typically from concurrently prescribed medications. Management of osteoporosis and other survivorship care is complex, and a multi-disciplinary approach is recommended with assessment of risk factors for bone loss, optimization of bone health through lifestyle approaches and pharmacological interventions based on evidence-based algorithms. This review examines the pathophysiology of bone loss and gives guidelines for the management of bone disease in women with breast cancer.
引用
收藏
页码:47 / 55
页数:9
相关论文
共 50 条
  • [11] Bone health in women with breast cancer
    Ramchand, S. K.
    Cheung, Y. M.
    Grossmann, M.
    CLIMACTERIC, 2019, 22 (06) : 589 - 595
  • [12] The Guidelines for the management of metastatic bone disease in breast cancer in the United Kingdom
    Bishop, HM
    Cameron, DA
    Coleman, R
    Davies, AM
    Dewar, JA
    Evans, A
    Evans, A
    Harnett, AN
    McCloskey, E
    O'Donoghue, D
    Pullicino, V
    Robertson, J
    Tillman, RM
    van Schaick, SH
    EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 1999, 25 (01): : 4 - 23
  • [13] Management of Bone Disease in Patients Undergoing Hormonal Therapy for Breast Cancer
    Mirza, Faryal Sardar Ali
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2011, 40 (03) : 549 - +
  • [14] Management of the contralateral breast in women with breast cancer
    Tuttle, T.
    CANCER RESEARCH, 2009, 69 (02) : 62S - 63S
  • [15] Management of bone metastases in breast cancer
    Lipton A.
    Current Treatment Options in Oncology, 2005, 6 (2) : 161 - 171
  • [16] Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
    Darby, Sarah C.
    Ewertz, Marianne
    McGale, Paul
    Bennet, Anna M.
    Blom-Goldman, Ulla
    Bronnum, Dorthe
    Correa, Candace
    Cutter, David
    Gagliardi, Giovanna
    Gigante, Bruna
    Jensen, Maj-Britt
    Nisbet, Andrew
    Peto, Richard
    Rahimi, Kazem
    Taylor, Carolyn
    Hall, Per
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (11): : 987 - 998
  • [17] Risk of ischemic heart disease in women after radiotherapy for breast cancer
    Riet, F. -G.
    Canova, C. -H.
    Bourgier, C.
    ONCOLOGIE, 2013, 15 (7-8) : 425 - 426
  • [18] MANAGEMENT OF BONE DISEASE IN CANCER
    Coleman, R.
    OSTEOPOROSIS INTERNATIONAL, 2021, 32 (SUPPL 1) : S37 - S38
  • [19] Management of the axilla in women with breast cancer
    Benson, J. R.
    della Rovere, G. Querci
    BREAST, 2007, 16 (02): : 130 - 136
  • [20] Management of menopause in women with breast cancer
    Vincent, A. J.
    CLIMACTERIC, 2015, 18 (05) : 690 - 701